लोड हो रहा है...
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...
में बचाया:
| में प्रकाशित: | Oncogene |
|---|---|
| मुख्य लेखकों: | , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Nature Publishing Group
2017
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/ https://ncbi.nlm.nih.gov/pubmed/28263969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|